Commenting on the approval, Makoto Sugita, Bristol Myers Squibb’s head of R&D in Japan, said, “We are very pleased that Breyanzi has been approved for use in the second-line treatment of relapsed or refractory LBCL, regardless of whether autologous hematopoietic stem-cell transplantation is intended. This approval is a major step forward for patients with refractory or relapsed LBCL who have undergone first-line therapy, as they may now benefit from a new treatment modality to bring them and their families more hope. We will continue to focus on the research and development of solutions for difficult-to-treat diseases with the aim of transforming patients’ lives through science.”
